15-PGDH inhibition promotes hematopoietic recovery and enhances HSC function during aging
Chaudhary, R.; Cordova, B. A.; Hong, M.; Klein, B. R.; Contreras, L. A.; Rashmil, R.; Goshevski, F.; Smith, J. N.; Taylor, D.; Pieper, A. A.; Markowitz, S. D.; Desai, A. B.
Show abstract
Hematopoietic aging is characterized by diminished stem cell regenerative capacity and an increased risk of hematologic dysfunction. We previously identified that the prostaglandin-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) regulates hematopoietic stem cell activity. Here, we expand on this work and demonstrate that in aged mice, (1) 15-PGDH expression and activity remain conserved in the bone marrow and spleen, suggesting it remains a viable therapeutic target in aging, (2) prolonged PGDH inhibition (PGDHi) significantly increases the frequency and number of phenotypic hematopoietic stem and progenitor cells across multiple compartments, with transcriptional changes indicative of enhanced function, (3) PGDHi-treated bone marrow enhances short-term hematopoietic recovery following transplantation, leading to improved peripheral blood output and accelerated multilineage reconstitution, and (4) PGDHi confers a competitive advantage in primary hematopoietic transplantation while mitigating age-associated myeloid bias in secondary transplants. Notably, these effects occur without perturbing steady-state blood production, suggesting that PGDHi enhances hematopoiesis under regenerative conditions while maintaining homeostasis. Our work identifies PGDHi as a translatable intervention to rejuvenate aged HSCs and mitigate hematopoietic decline. Significance StatementWe identify 15-hydroxyprostaglandin dehydrogenase inhibition (PGDHi) as a strategy to enhance hematopoietic stem cell function in aging. In aged mice, PGDHi expands stem and progenitor populations, accelerates hematopoietic recovery after transplantation, and reduces myeloid bias while maintaining steady-state blood production. These findings highlight a potential therapeutic approach to restore hematopoietic resilience and improve regenerative outcomes in aging. Graphical Abstract15-prostaglandin dehydrogenase inhibition ameliorates multiple facets of age-related hematopoietic decline. Schematic made using BioRender.com. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=114 SRC="FIGDIR/small/648417v1_ufig1.gif" ALT="Figure 1"> View larger version (18K): org.highwire.dtl.DTLVardef@1952ad9org.highwire.dtl.DTLVardef@30169aorg.highwire.dtl.DTLVardef@11bec0corg.highwire.dtl.DTLVardef@2617c8_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- 15-PGDH Inhibition Activates the Splenic Niche to Promote Hematopoietic Regeneration 97%
- Targeting fatty acid beta-oxidation impairs monocyte differentiation and prolongs heart allograft survival 94%
- Aging imparts cell-autonomous dysfunction to regulatory T cells during recovery from influenza pneumonia 93%
Similar papers in this journal
- Transplacental innate immune training via maternal microbial exposure: a central role for the XBP1-ERN1 axis in programming dendritic cell precursors 94%
- Deletion of Vhl in Dmp1-expressing cells causes microenvironmental impairment of B cell lymphopoiesis 93%
- Unrestrained Gαi2 Signaling Disrupts Normal Neutrophil Trafficking, Aging, and Clearance 93%
Similar papers in this journal
- Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation 95%
- U2AF1 is a haplo-essential gene required for cancer cell survival 94%
- Disturbing immune homeostasis by neutrophil loss of Uba1 induces VEXAS-like autoinflammatory disease in mice 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.